Brief: Elevation Oncology Announces CEO Transition, Pipeline Prioritization

Elevation Oncology

06/01/2023 13:26

Jan 6 (Reuters) - Elevation Oncology Inc  ELEV.O :
    * ELEVATION ONCOLOGY ANNOUNCES PIPELINE PRIORITIZATION,
REALIGNMENT OF RESOURCES TO ADVANCE EO-3021 AND CEO TRANSITION
    * ELEVATION ONCOLOGY INC - PAUSING FURTHER INVESTMENT IN
CLINICAL
DEVELOPMENT OF SERIBANTUMAB
    * ELEVATION ONCOLOGY - PRIORITIZING DEVELOPMENT OF EO-3021 &
ADDITIONAL PIPELINE PROGRAMS INCLUDING THOSE THROUGH EXISTING
PARTNERSHIP WITH CARIS LIFE SCIENCES
    * ELEVATION ONCOLOGY INC - SHAWN LELAND HAS RESIGNED AS CEO
    * ELEVATION ONCOLOGY - REALIGNING RESOURCES TO FOCUS ON
ADVANCING
EO-3021, ADDITIONAL PIPELINE PROGRAMS EXPECTED TO EXTEND CASH
RUNWAY INTO Q4 OF 2024
    * ELEVATION ONCOLOGY INC - INTENDS TO PURSUE FURTHER
DEVELOPMENT
OF SERIBANTUMAB ONLY IN COLLABORATION WITH A PARTNER
    * ELEVATION ONCOLOGY INC - ANNOUNCES APPROXIMATELY 30%
REDUCTION
IN WORKFORCE
    * ELEVATION ONCOLOGY INC - JOSEPH FERRA, CFO, APPOINTED AS
INTERIM
CEO
    * ELEVATION ONCOLOGY INC - AS OF DEC 31, 2022, CO HAD
PRELIMINARY
UNAUDITED CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES
TOTALING $90.3 MILLION

Source text for Eikon:  ID:nPnbJ2Pl1a 
Further company coverage:  ELEV.O 
 ((Reuters.Briefs@thomsonreuters.com;))